J

    Jaguar Animal Health Inc (JAGX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.79
    -0.02 (-2.32%)

    Market Cap: $4.19M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(23/36)
    Avg Surprise
    -392.39%
    Streak
    1 Q

    Upcoming Estimates

    Mar 31, 2026
    EPS Consensus$-2.04
    Range$-2.04 - $-2.04
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-7.50-267.6%
    60d ago$-7.50-267.6%
    30d ago$-7.50-267.6%
    7d ago$-7.50-267.6%
    Current$-2.04
    Revenue Consensus
    $0
    Range$0 - $0
    0 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Mar 26EST
    		-$-2.04---
    Jun 26
    		$-15.70N/A+69.89%Beat+99.6%
    Sep 25
    		$-219.80$-177.80-23.62%Miss+76.1%
    Jun 25
    		$-259.26$-249.55-3.89%Miss+92.7%
    Mar 25
    		$-16.70$-10.82-54.34%Miss+99.5%
    Dec 24
    		$-4403.00$-647.50-580.00%Miss-13242.4%
    Sep 24
    		$-918.75N/A+55.70%Beat+95.4%
    Jun 24
    		$-3535.00$-1050.00-236.67%Miss+90.2%
    Mar 24
    		$-3459.75$-1575.00-119.67%Miss+97.2%
    Dec 23
    		$-33.00N/A+55.28%Beat-862.2%
    Sep 23
    		$-19949.98N/A+69.11%Beat+95.8%
    Jun 23
    		$-36224.96N/A+54.90%Beat+92.3%
    Mar 23
    		$-125474.87$-236250.35+46.89%Beat+87.5%
    Dec 22
    		$-3.43N/A+64.82%Beat+85.2%
    Sep 22
    		$-472500.71$-275625.41-71.43%Beat+52.7%
    Jun 22
    		$-472500.71$-748126.12+36.84%Beat+52.7%
    Mar 22
    		$-1000000.00$-708751.06-41.09%Beat+0.0%
    Dec 21
    		$-23.25$-6.75-244.44%Miss+31.1%
    Sep 21
    		$-1000000.00$-787501.18-26.98%Beat+0.0%
    Jun 21
    		$-1000000.00$-354375.57-182.19%Beat+0.0%
    Mar 21
    		$-1000000.00$-236250.38-323.28%Beat+0.0%
    Dec 20
    		$-33.75$-22.50-50.00%Miss+100.0%
    Sep 20
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Jun 20
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Mar 20
    		$-1000000.00$-1000000.00+0.00%Beat-266666566.6%
    Sep 19
    		$-1000000.00$-1000000.00+0.00%Beat-196078331.4%
    Jun 19
    		$-1000000.00$-1000000.00+0.00%Beat-1428571528.4%
    Mar 19
    		$-1000000.00$-1000000.00+0.00%Beat-1904661.9%
    Dec 18
    		$-0.38$-0.07-435.71%Miss-635.7%
    Sep 18
    		$-0.51$-0.45-13.33%Miss+99.2%
    Jun 18
    		$0.07N/A+115.56%Beat+100.1%
    Mar 18
    		$-52.50$-0.60-8650.00%Miss-950.0%
    Dec 17
    		$0.07$0.00N/ABeat+100.0%
    Sep 17
    		$-63.00N/A+53.85%Beat+80.0%
    Jun 17
    		$-126.00$-231.00+45.45%Beat-
    Mar 17
    		$-5.00$-0.13-3746.15%Miss-
    Dec 16
    		$-294.00$-252.00-16.67%Miss-
    Sep 16
    		$-315.00$-420.00+25.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.00EV/EBITDA-0.63x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-130.80%Operating Margin-620.00%
    ROE-549.00%ROIC-113.34%
    Financial Health
    Debt/Equity2.35xInterest Coverage-6.23x
    Current Ratio0.69xQuick Ratio0.40x
    Trading Statistics
    Beta-0.05Avg Volume190.29K
    52-Week High$85.4052-Week Low$0.72

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.89
    SMA 20$0.89
    SMA 50$1.53
    SMA 200$14.75
    EMA 10$0.87
    EMA 20$0.96
    EMA 50$1.87
    EMA 200$27.15

    MACD

    Line: -0.18Signal: -0.23Hist: 0.05

    ADX

    ADX: 25.4+DI: 17.3-DI: 23.1

    Aroon & PSAR

    Aroon Up28.0
    Aroon Down48.0
    PSAR$1.03

    Bollinger Bands

    Upper Band$1.05
    Lower Band$0.73
    %B Position3545%(Upper)
    Band Width0.19

    RSI (14-Day)

    Neutral
    31.2

    Momentum Oscillators

    Stoch %K30.8
    Stoch %D43.5
    Williams %R-79.0
    ROC (10d)-10.0%
    Momentum-0.09
    CCI (20d)-127.7
    MFI (14d)75.1

    Volatility Measures

    ATR (14d)$0.16(19.8%)
    StdDev (20d)0.08
    Hist Vol111.3%(High)

    Volume Flow

    VWAP$0.78
    OBV95.5M
    AD Line180.3B
    CMF (20d)-0.076

    Volume Metrics

    Avg Vol (20d)194.7K
    Vol Ratio0.2x(Low)
    VWMA (20d)$0.90

    Pivot Points

    R3$0.91
    R2$0.89
    R1$0.85
    Pivot Point$0.82
    S1$0.78
    S2$0.76
    S3$0.72

    Advanced Oscillators

    TSI-36.42
    Ultimate Osc36.7
    KST-300.09

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.23M$20.27M$3.23M$3.08M$2.98M$2.21M$3.51M$3.11M$2.72M$2.35M$2.30M$2.81M
    Cost of Revenue$1.03M$1.16M$2.20M$532,000$527,000$515,000$557,000$541,000$427,000$430,000$687,000$514,000
    Gross Profit$194,000$19.11M$1.03M$2.55M$2.45M$1.70M$2.95M$2.57M$2.29M$1.92M$1.61M$2.30M
    Operating Expenses$7.79M$8.93M$22.28M$9.79M$10.46M$11.12M$11.11M$9.83M$9.49M$10.14M$9.17M$11.09M
    R&D$3.34M$3.93M$14.31M$3.66M$3.27M$3.73M$4.53M$4.04M$3.65M$4.31M$3.46M$6.08M
    SG&A$4.45M$4.11M$4.89M$4.13M$4.73M$4.90M$3.86M$3.78M$4.31M$4.38M$3.81M$3.53M
    Operating Income$-7,597,000$10.18M$-21,242,000$-7,238,000$-8,007,000$-9,421,000$-8,157,000$-7,262,000$-7,197,000$-8,215,000$-7,557,000$-8,787,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$3.67M$1.33M$109,000$6,000$1.81M$-56,000$-110,000$-162,000$-108,000$-634,000$248,000$-3,197,000
    Income Before Tax$-12,802,000$8.72M$-23,193,000$-9,648,000$-10,560,000$-10,596,000$-10,234,000$-10,021,000$-9,628,000$-9,368,000$-9,309,000$-7,904,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-12,802,000$8.72M$-23,193,000$-9,648,000$-10,560,000$-10,596,000$-10,234,000$-10,021,000$-9,628,000$-9,368,000$-9,309,000$-7,904,000
    EBITDA$-8,163,000$10.57M$-22,388,000$-9,085,000$-8,197,000$-10,106,000$-9,751,000$-9,587,000$-9,177,000$-9,118,000$-6,746,000$-3,389,000
    EBIT$-9,137,000$10.05M$-23,084,000$-9,642,000$-8,753,000$-10,652,000$-10,344,000$-10,183,000$-9,736,000$-10,002,000$-9,047,000$-11,101,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about JAGX

    News

    Jaguar Health presents crofelemer data at ESPGHAN 2026

    Jaguar Health's family company, Napo Pharmaceuticals, presented new data at ESPGHAN 2026, showcasing the effectiveness of oral liquid crofelemer in reducing parenteral support for pediatric intestinal failure patients with Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF). The company aims for Breakthrough Therapy designation for MVID and plans an NDA filing in mid-2027, while also seeking non-dilutive funds through business development discussions. Separately, Jaguar Health converted its Series O Convertible Preferred Stock into common stock, which automatically took effect on June 25, 2026.

    scanx.trade•8/24/26•
    Bullish

    Jaguar Health: Sales And Marketing Spending Reduced More Than 99% After Future Pak Licensing Deal

    Jaguar Health significantly reduced its quarterly sales and marketing expenses by over 99% after transferring U.S. commercial responsibilities for Mytesi and Canalevia-CA1 to Future Pak. This strategic shift resulted in a substantial change in the company's cost structure and revenue model, allowing Jaguar to focus resources on developing crofelemer for rare intestinal-failure disorders. Despite a decrease in reported prescription product revenue due to the new licensing model, the company saw an increase in Mytesi bottles sold and secured non-dilutive capital from the Future Pak agreement.

    Pulse 2.0•8/22/26•
    Somewhat-Bullish

    Jaguar Health | 10-Q: Quarterly report

    This document is a 10-Q quarterly report filed by Jaguar Health. The content is a standard regulatory filing.

    Moomoo•8/20/26•
    Neutral

    Jaguar Health Reports Second Quarter 2026 Financials

    Jaguar Health, Inc. reported its consolidated second-quarter 2026 financial results, highlighting a strategic shift towards rare disease indications with its crofelemer drug. The company recognized significant license revenues from a new U.S. commercial licensing agreement with Future Pak, impacting prescription product revenues. While operational loss decreased, the net loss attributable to common shareholders increased due to various financial adjustments.

    ACCESS Newswire•8/20/26•
    Somewhat-Bullish

    Jaguar Health Q2 loss narrows 96% as revenue falls 59% on licensing shift

    Jaguar Health reported a 96% narrowing of its net loss per share in Q2 2026, despite a 59% revenue decline. This shift is attributed to a strategic licensing agreement with Future Pak, which provided an $18 million upfront payment and significantly reduced sales and marketing expenses. The company is now focusing on R&D for rare intestinal failure diseases, with an NDA for crofelemer anticipated in Q2 2027.

    scanx.trade•8/19/26•
    Somewhat-Bullish

    Frequently Asked Questions About JAGX

    Does JAGX pay dividends?
    Jaguar Animal Health Inc (JAGX) does not currently pay a regular dividend.
    What is JAGX's market cap?
    Jaguar Animal Health Inc (JAGX) has a market capitalization of $4.19M with a current stock price of $0.79.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In